NCT05096234 is a Phase 1 clinical trial of [ 18F]F-AraG PET in Non-Hodgkin's Lymphoma, sponsored by Stanford University.

Who is sponsoring NCT05096234?

NCT05096234 is sponsored by Stanford University.

What drugs are being tested in NCT05096234?

Interventions in NCT05096234: [ 18F]F-AraG PET.

What condition does NCT05096234 study?

NCT05096234 studies Non-Hodgkin's Lymphoma.

Is NCT05096234 still recruiting?

NCT05096234 is currently terminated. Last updated 6 February 2025.

Last reviewed 2025-02-06 · How we verify

NCT05096234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Terminated Phase 1 Last updated 6 February 2025

What this trial tests

Phase 1 trial testing [ 18F]F-AraG PET in Non-Hodgkin's Lymphoma in 2 participants. Terminated before completion.

Timeline

28 September 2021

Primary endpoint
9 May 2022

9 October 2023

Quick facts

Lead sponsor	Stanford University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	2
Start date	28 September 2021
Primary completion	9 May 2022
Estimated completion	9 October 2023
Sites	1 location across United States

Drugs / interventions tested

[ 18F]F-AraG PET

Conditions studied

Non-Hodgkin's Lymphoma — all drugs for Non-Hodgkin's Lymphoma →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.
Shankar LK, Schöder H, Sharon E, Wolchok J, et al · · 2023 · cited 21× · PMID 36858729 · DOI 10.1016/s1470-2045(22)00742-2
Imaging of Activated T Cells.
Sako MO, Larimer BM. · · 2023 · cited 12× · PMID 36460341 · DOI 10.2967/jnumed.122.264097
Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.
Martin S, Wendlinger L, Zitti B, Hicham M, et al · · 2024 · cited 3× · PMID 39196448 · DOI 10.1186/s13550-024-01142-1
Recent Updates of PET in Lymphoma: FDG and Beyond.
Kim SY, Chung HW, So Y, Lee MH, et al · · 2024 · cited 2× · PMID 39595051 · DOI 10.3390/biomedicines12112485
Illuminating immunotherapy response via precision T cell-targeted PET imaging.
Glazer SE, Kummar S, Mittra E. · · 2024 · cited 2× · PMID 39104861 · DOI 10.3389/fmed.2024.1233913
Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.
Almutairi WM, Gopaulchan M, Bhaskara R, Zheng QH, et al · · 2026 · PMID 42001384 · DOI 10.1186/s13550-026-01436-6

Verify or expand the search:

Other recruiting trials for Non-Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
NCT04532203 — A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna · EARLY_PHASE1 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05096234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 6 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05096234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing